申请人:AstraZeneca AB
公开号:US10273227B2
公开(公告)日:2019-04-30
The invention concerns compounds of Formula (I):
or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating KIT mediated diseases.
本发明涉及式(I)化合物:
或其药学上可接受的盐,其中 R1、R2、R3 和 R4 具有本文在描述中定义的任何含义;它们的制备工艺;含有它们的药物组合物以及它们在治疗 KIT 介导的疾病中的用途。